Clinical trial
Phase II Trial of Erlotinib in Advanced Pancreatic Cancer
NCT00497224 · University Health Network, Toronto, Other · Completed
Key facts
| NCT number | NCT00497224 |
|---|---|
| Title | Phase II Trial of Erlotinib in Advanced Pancreatic Cancer |
| Official title | Phase II Trial of Erlotinib in Advanced Pancreatic Cancer |
| Lead sponsor | University Health Network, Toronto, Other |
| Collaborators | OSI Pharmaceuticals Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Cancer, Pancreas |
| Intervention type | Drug |
| Interventions | Erlotinib |
| Enrollment | 51 |
| Start date | Nov 1, 2006 |
| Primary completion | Dec 1, 2008 |
| Completion | Jun 1, 2013 |
| First posted | Jul 6, 2007 |
| Last update posted | May 30, 2019 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: